Zanaflex News
Acorda Therapeutics Q4 Loss Widens On Expenses [ACOR] - RTT News
The company reported gross sales of Zanaflex Capsules of $11.8 million and gross sales of Zanaflex of $1.0 million, providing combined gross sales of $12.8 ...
Earnings roundup: Loews, Napco - Forbes
... Therapeutics Inc. said Monday its fourth-quarter loss widened on higher operating expenses, but sales of its drug Zanaflex helped drive revenue higher. ...
Acorda Therapeutics' 4Q Loss Widens - Houston Chronicle
Revenue rose 45 percent to $11.2 million from $7.7 million, benefiting from gross sales of its anti-muscle spasm drug Zanaflex totaling $12.8 million. ...
Earnings Roundup: Loews, Napco - Houston Chronicle
... Therapeutics Inc. said Monday its fourth-quarter loss widened on higher operating expenses, but sales of its drug Zanaflex helped drive revenue higher. ...
Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 ... - Business Wire (press release)
all 11 news articles
Acorda Therapeutics, Inc. Announces Proposed Public Offering of ... - FOXBusiness
The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ...
Acorda sinks on forecast wider 2008 loss - BusinessWeek
In the same SEC filing, Acorda said it expects to post a loss of $14 million during the fourth quarter, as sales of the muscle relaxant Zanaflex reached $12 ...
Acorda Sinks on Forecast Wider 2008 Loss - Houston Chronicle
In the same SEC filing, Acorda said it expects to post a loss of $14 million during the fourth quarter, as sales of the muscle relaxant Zanaflex reached $12 ...
Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre ... - FOXBusiness
The Company's marketed products include Zanaflex Capsules(R) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. ...
Out of the Gate: Acorda Therapeutics - Houston Chronicle
Acorda's only drug on the market is Zanaflex, a muscle relaxant. The company has two other drug candidates in preclinical development, and a third in the ...
Zanaflex RSS Feed